Bexorg is transforming central nervous system drug discovery with the world's first integrated AI and whole-human brain platform. Spun out of Yale University in 2021, the company has raised $42.5 million to address the 95% clinical trial failure rate in CNS drug development. Using their proprietary BrainEx technology, Bexorg restores molecular activity in donated human brains to create the first intact human brain laboratory for drug discovery. Over the last 18 months, Bexorg has completed hundreds of whole-brain experiments spanning Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions, establishing one of the world's largest repositories of dynamic human CNS data.
The company's platform integrates direct human brain experimentation with advanced AI models trained on petabyte-scale molecular data. This approach enables pharmaceutical partners to validate targets, discover biomarkers, and make go/no-go decisions with unprecedented accuracy. Bexorg has formed strategic partnerships with leading organizations including Biohaven, the University of Oxford, and the UK Medical Research Council. With operations in New Haven, CT and San Francisco, CA, Bexorg's mission is to end CNS clinical trial failures and deliver effective therapies to the more than 70 million people worldwide affected by devastating neurological diseases.